CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 1, 2026 to 47 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Pla...
CONSHOHOCKEN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on May 1, 2026 to 47 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).
Largest acquisition contract quarter since 2022; resale margin improved every month since September 2025, with March 2026 delivering higher contribution margin than any quarter since 2Q24; aged inventory decreased to 10% from 51% in 3Q25; and both 4Q25 and January 2026 cohorts are the best cash acquisition cohorts in Opendoor history (ex-COVID era) Largest acquisition contract quarter since 2022; ...
Largest acquisition contract quarter since 2022; resale margin improved every month since September 2025, with March 2026 delivering higher contribution margin than any quarter since 2Q24; aged inventory decreased to 10% from 51% in 3Q25; and both 4Q25 and January 2026 cohorts are the best cash acquisition cohorts in Opendoor history (ex-COVID era) Largest acquisition contract quarter since 2022; resale margin improved every month since September 2025, with March 2026 delivering higher contribution margin than any quarter since 2Q24; aged inventory decreased to 10% from 51% in 3Q25; and both 4Q25 and January 2026 cohorts are the best cash acquisition cohorts in Opendoor history (ex-COVID era)
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 89,250 shares of its common stock to 12 newly...
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 89,250 shares of its common stock to 12 newly-hired employees, with a grant date of May 5, 2026 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.
Getty Images By James Picerno A new peace proposal to end the war is reportedly under consideration between the US and Iran. Its success or failure will be a key driver of inflation risk, which has climbed since the conflict sent
Getty Images By James Picerno A new peace proposal to end the war is reportedly under consideration between the US and Iran. Its success or failure will be a key driver of inflation risk, which has climbed since the conflict sent
Expedia press release ( EXPE ): Q1 Non-GAAP EPS of $1.96 beats by $0.58 . Revenue of $3.43B (+14.7% Y/Y) beats by $80M . Business Outlook Fiscal Year 2026 Q2 2026 Metric Previous Guidance Current Guidance Gross bookings Revenue Adjusted EBITDA margin expansion** +1 - 1.25pts +1 - 1.25pts 0.5 - 1pt Click to enlarge Shares -1.9% AH. More on Expedia Expedia Group: Price Recovery In Line With Valuatio...
Expedia press release ( EXPE ): Q1 Non-GAAP EPS of $1.96 beats by $0.58 . Revenue of $3.43B (+14.7% Y/Y) beats by $80M . Business Outlook Fiscal Year 2026 Q2 2026 Metric Previous Guidance Current Guidance Gross bookings Revenue Adjusted EBITDA margin expansion** +1 - 1.25pts +1 - 1.25pts 0.5 - 1pt Click to enlarge Shares -1.9% AH. More on Expedia Expedia Group: Price Recovery In Line With Valuation And Strategic Business Model Expedia: Margin Expansion Supports Re-Entry Opportunity Expedia: With Global Risks Mounting, It's Time To Lock In Gains (Downgrade) Expedia Q1 2026 Earnings Preview Expedia Group appoints Derek Andersen as CFO
The White House called Star Wars star Mark Hamill “one sick individual” on Thursday after an AI-generated image of US President Donald Trump in a shallow grave was posted on one of the actor’s social media accounts. “If Only” was inscribed on the image of Trump lying with his eyes closed next to a gravestone, surrounded by daisies, with the inscription “Donald J Trump 1946-2024”. The image was...
The White House called Star Wars star Mark Hamill “one sick individual” on Thursday after an AI-generated image of US President Donald Trump in a shallow grave was posted on one of the actor’s social media accounts. “If Only” was inscribed on the image of Trump lying with his eyes closed next to a gravestone, surrounded by daisies, with the inscription “Donald J Trump 1946-2024”. The image was posted on Hamill’s verified Bluesky account. Hamill, who played Luke Skywalker in the classic Star...
Amazon.com ( AMZN ) shares snapped six straight sessions of gains on Thursday, as the stock was 1.4% lower at $271.14. The e-commerce and cloud computing giant gained 4.5% in the preceding six sessions. So far this year, the stock has added 19%, compared to the 7% rise in the
Amazon.com ( AMZN ) shares snapped six straight sessions of gains on Thursday, as the stock was 1.4% lower at $271.14. The e-commerce and cloud computing giant gained 4.5% in the preceding six sessions. So far this year, the stock has added 19%, compared to the 7% rise in the
Solskin/DigitalVision via Getty Images Tyler Technologies ( TYL ) might not be a household name but if you've ever paid a property tax bill online, looked up a court record, or registered your dog with the city, there is a very high chance you
Solskin/DigitalVision via Getty Images Tyler Technologies ( TYL ) might not be a household name but if you've ever paid a property tax bill online, looked up a court record, or registered your dog with the city, there is a very high chance you
JHVEPhoto/iStock Editorial via Getty Images Beyond Meat, Inc. ( BYND ) continues to struggle with weak sales and minimal gross margins, resulting in it delivering negative $27.8 million in adjusted EBITDA in Q1 2026 . Beyond Meat is searching for a way
JHVEPhoto/iStock Editorial via Getty Images Beyond Meat, Inc. ( BYND ) continues to struggle with weak sales and minimal gross margins, resulting in it delivering negative $27.8 million in adjusted EBITDA in Q1 2026 . Beyond Meat is searching for a way
SANTA CLARA, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of comprehensive data solutions for the semiconductor and electronics ecosystem, today announced financial results for its first quarter ended March 31, 2026.
SANTA CLARA, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of comprehensive data solutions for the semiconductor and electronics ecosystem, today announced financial results for its first quarter ended March 31, 2026.
Getty Images The Beyond Meat Investment Thesis Beyond Meat, Inc. ( BYND ) presented its latest quarterly results yesterday evening. While the EPS and revenue figures were broadly in line with analysts' expectations, the stock price fell by
Getty Images The Beyond Meat Investment Thesis Beyond Meat, Inc. ( BYND ) presented its latest quarterly results yesterday evening. While the EPS and revenue figures were broadly in line with analysts' expectations, the stock price fell by
Gilead Sciences Inc. said it now expects to book a loss in 2026 on $11.5 billion in charges after deals to acquire a string of companies making experimental cancer and autoimmune disease drugs. The planned charges come as the company reported first-quarter earnings and revenue that beat analysts’ expectations on growing HIV drug sales, including a strong initial rollout of a new HIV prevention dru...
Gilead Sciences Inc. said it now expects to book a loss in 2026 on $11.5 billion in charges after deals to acquire a string of companies making experimental cancer and autoimmune disease drugs. The planned charges come as the company reported first-quarter earnings and revenue that beat analysts’ expectations on growing HIV drug sales, including a strong initial rollout of a new HIV prevention drug, Yeztugo. For the year, the company said it expects product sales between $30 billion and $30.4 billion, up from its previous guidance of $29.6 billion to $30 billion. But as a result of the deal-related charges, the company now expects an adjusted per-share loss of $1.05 to $0.65, Gilead said in a statement Thursday. That’s down from a previous profit target of $8.65 a share at the midpoint. Gilead shares fell 3.3% in trading after New York markets closed. They had gained 9% this year through Thursday’s close. Gilead executives in an interview said that the charges would come in the second quarter and were entirely related to the transactions. The underlying business showed a strong first quarter of “demand driven growth,” Gilead Chief Executive Officer Daniel O’Day said in an interview. He said the company has been looking for years for deals to supplement its portfolio, and it just happened that three came to fruition in the first part of this year. Gilead dominates the HIV antiviral field but in the last few years has been aggressively trying to expand into new growth areas, including cancer and autoimmune therapies. It’s digesting acquisitions it announced in the first few months of the year to beef up its portfolio of experimental drugs. In February, the company said it would buy the cancer-focused biotech Arcellx Inc. for as much as $7.8 billion; the transaction closed in April. The company warned at the time that it would hurt its outlook. Gilead also agreed in March to purchase Ouro Medicines, a closely held company testing antibody drugs against autoimmune disea...
(RTTNews) - Enel (ENL.DE) reported first-quarter results on Thursday, with profit declining from last year as lower revenue offset modest growth in EBITDA.
(RTTNews) - Enel (ENL.DE) reported first-quarter results on Thursday, with profit declining from last year as lower revenue offset modest growth in EBITDA.
JACKSONVILLE, FL / ACCESS Newswire / May 7, 2026 / ParkerVision, Inc. (OTCQB:PRKR) ("ParkerVision" or the "Company"), a developer and marketer of technologies and products for wireless applications, today announced results for the three months ended ...
JACKSONVILLE, FL / ACCESS Newswire / May 7, 2026 / ParkerVision, Inc. (OTCQB:PRKR) ("ParkerVision" or the "Company"), a developer and marketer of technologies and products for wireless applications, today announced results for the three months ended ...
With transport set to be Australia’s top-emitting sector by 2030, officials have recognised the need to invest At Penrith, a suburb on Sydney’s rural fringe 50km (30 miles) west of the central business district, you can catch a train to the city every four to eight minutes during the morning peak, and roughly every 10 to 15 minutes during off-peak hours before midnight. On an express service, it t...
With transport set to be Australia’s top-emitting sector by 2030, officials have recognised the need to invest At Penrith, a suburb on Sydney’s rural fringe 50km (30 miles) west of the central business district, you can catch a train to the city every four to eight minutes during the morning peak, and roughly every 10 to 15 minutes during off-peak hours before midnight. On an express service, it takes 52 minutes to Sydney’s Central station, comparable to the journey by car, without factoring in the morning traffic on a tolled motorway. Continue reading...